Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Targeting Protein Arginine Methylation to Reprogram Tumor Macrophages
EF 2025-26
Résumé
Breast cancer (BC) is the leading cause of female cancer-related mortality, and remains the most prevalent cancer for women worldwide. Each year, there are over two million cases, and over half a million deaths. While substantial advances have been made in precision therapeutics, patients diagnosed with BC often relapse, indicating a need to identify novel therapeutic targets. Enzymes known as protein arginine methyltransferases (PRMTs) catalyze the posttranslational methylation of RNA-binding proteins, responsible for regulating RNA splicing and DNA damage repair, which are important in cancer, thus highlighting PRMTs as potential BC targets. However, in BC, as well as other cancers, immune cells, like macrophages, are crucial in identifying cancer cells, to either destroy them or promote cancer cell growth. Though the effect of targeting PRMTs on immune cells is not yet known. In BC, macrophages make up a large proportion of the tumor, and while normal macrophages are inflammatory and can fight infection and cancer, BC macrophages are anti-inflammatory and support the tumor cells. Since high infiltration of anti-inflammatory macrophages in tumors has been linked with poor patient prognosis, targeting macrophages to elicit an inflammatory response in cancer remains paramount. Previous research has indicated that RNA splicing greatly influences macrophage pro/anti-inflammatory properties and that PRMTs are overexpressed in macrophages. By understanding the effect of arginine methylation on the immune response and the role of PRMT inhibition and splicing on macrophage activation states, we will establish a rationale for developing PRMT-based therapies for BC treatment.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572580
Name
Lebon Ilana
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting Protein Arginine Methylation to Reprogram Tumor Macrophages
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Arginine Methylation; Breast Cancer; Gene Expression; Macrophages; Protein Arginine Methyltransferases; Splicing
Abstract
Breast cancer (BC) is the leading cause of female cancer-related mortality, and remains the most prevalent cancer for women worldwide. Each year, there are over two million cases, and over half a million deaths. While substantial advances have been made in precision therapeutics, patients diagnosed with BC often relapse, indicating a need to identify novel therapeutic targets. Enzymes known as protein arginine methyltransferases (PRMTs) catalyze the posttranslational methylation of RNA-binding proteins, responsible for regulating RNA splicing and DNA damage repair, which are important in cancer, thus highlighting PRMTs as potential BC targets. However, in BC, as well as other cancers, immune cells, like macrophages, are crucial in identifying cancer cells, to either destroy them or promote cancer cell growth. Though the effect of targeting PRMTs on immune cells is not yet known. In BC, macrophages make up a large proportion of the tumor, and while normal macrophages are inflammatory and can fight infection and cancer, BC macrophages are anti-inflammatory and support the tumor cells. Since high infiltration of anti-inflammatory macrophages in tumors has been linked with poor patient prognosis, targeting macrophages to elicit an inflammatory response in cancer remains paramount. Previous research has indicated that RNA splicing greatly influences macrophage pro/anti-inflammatory properties and that PRMTs are overexpressed in macrophages. By understanding the effect of arginine methylation on the immune response and the role of PRMT inhibition and splicing on macrophage activation states, we will establish a rationale for developing PRMT-based therapies for BC treatment.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lebon, Ilana
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~